Expert committee to consider SII s emergency use approval for COVID-19 vaccine ANI | Updated: Dec 30, 2020 15:08 IST
New Delhi [India], December 30 (ANI): Subject Expert Committee (SEC) of Drugs Controller of India will take a meeting to consider Serum Institute of India s application for emergency use approval of its COVID-19 vaccine, says a government official.
According to the sources, only Serum Institute s application will be considered.
The recommendation of SEC will be sent for drug regulator s approval, later today after the meeting.
Covishield is being manufactured on the Chimpanzee Adenovirus platform and by the SII in Pune. The collaborative company is Astrazeneca. The regulator had allowed the phase 2 and 3 clubbed clinical trials of the vaccine to them and they have applied for emergency use authorisation, he said.
According to the sources, only Serum Institute s application will be considered.
The recommendation of SEC will be sent for drug regulator s approval later today after the meeting.
Covishield is being manufactured on the Chimpanzee Adenovirus platform and by the SII in Pune. The collaborative company is AstraZeneca. The regulator had allowed the phase 2 and 3 clubbed clinical trials of the vaccine to them and they have applied for emergency use authorisation, he said.
The SII is the first indigenous company that has sought emergency approval for the vaccine developed along with global pharma giant AstraZeneca and Oxford University.
The Pune-based company earlier stated that ChAdOx1 nCov-2019 coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years of age.
Expert committee to consider Serum Institute s emergency use approval for COVID-19 vaccine
The SII is the first indigenous company that has sought emergency approval for the vaccine developed along with global pharma giant AstraZeneca and Oxford University.
Share Via Email
| A+A A- By ANI
NEW DELHI: Subject Expert Committee (SEC) of Drugs Controller of India will take a meeting to consider Serum Institute of India s application for emergency use approval of its COVID-19 vaccine, says a government official.
According to the sources, only Serum Institute s application will be considered.
The recommendation of SEC will be sent for drug regulator s approval, later today after the meeting.
India to play vital role in equitable distribution of COVID-19 vaccines around the world: Pharma industry financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.